- cafead Jun 03, 2021 at 12:12: AM
via As Novartis’ Kisqali for breast cancer trails Pfizer’s Ibrance in sales, the Swiss biopharma continues to trot out long-term survival data it hopes will flesh out the drug’s overall profile.
Ahead of #ASCO21 this weekend, Novartis teased out more data for the CDK4/6 inhibitor for postmenopausal HR-positive, HER2-negative metastatic breast cancer patients. With more than four years of follow-up, Kisqali in combination with AstraZeneca’s Faslodex provided more than a year of extra survival benefit compared to Faslodex alone.
article source
Ahead of #ASCO21 this weekend, Novartis teased out more data for the CDK4/6 inhibitor for postmenopausal HR-positive, HER2-negative metastatic breast cancer patients. With more than four years of follow-up, Kisqali in combination with AstraZeneca’s Faslodex provided more than a year of extra survival benefit compared to Faslodex alone.
article source